(NVS) Novartis AG BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NVS) Novartis AG Complete Analysis Pack
Unlock Strategic Clarity
This Novartis AG BCG Matrix helps you quickly see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Stars
Entresto, $7.8bn 2024 sales
Entresto was Novartis AG’s biggest product in 2024, with sales of $7.8bn. Heart-failure demand stayed strong across major markets, and the drug kept growing as diagnosis and treatment rates improved. In the BCG Matrix, it stays a Star: high growth, high share, and still room to reach more eligible patients.
Cosentyx, $6.1bn 2024 sales
Cosentyx stayed above $6.0bn in 2024, with sales of $6.1bn, keeping Novartis AG's immunology franchise in the Stars zone. It has broad use in psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Scale, strong physician trust, and wide label support keep Cosentyx in a leading market position.
Kisqali, $3.0bn 2024 sales
Kisqali delivered $3.0bn in 2024 sales, confirming strong Star status in Novartis AG's BCG mix. Growth was driven by wider use in HR-positive, HER2-negative breast cancer, where uptake kept rising across earlier-line treatment. It remains one of Novartis AG's fastest-growing oncology assets.
Kesimpta, $3.0bn 2024 sales
Kesimpta was a clear Star in Novartis AG’s BCG matrix, with 2024 sales of $3.0bn. The multiple-sclerosis drug kept growing off a rising installed base, showing strong repeat demand in a large chronic specialty market. Its scale and growth make it one of Novartis AG’s main revenue engines.
- 2024 sales: $3.0bn
- Growth driver: expanding installed base
- Market: chronic multiple sclerosis therapy
Pluvicto, $1.4bn 2024 sales
Pluvicto is a Star in Novartis AG’s BCG matrix: 2024 sales reached $1.4bn, showing the radioligand therapy scaled fast after launch. Prostate-cancer uptake kept rising through 2024 as more centers adopted the treatment and access broadened. This is now a high-growth oncology platform with room to expand further.
- 2024 sales: $1.4bn
- Fast post-launch scale
- Rising prostate-cancer uptake
- Expanding access
Novartis’ Star Drugs Power Strong 2024 Growth
Novartis AG’s Stars are Entresto, Cosentyx, Kisqali, Kesimpta, and Pluvicto. Together, they drove strong 2024 momentum: Entresto sold $7.8bn, Cosentyx $6.1bn, Kisqali $3.0bn, Kesimpta $3.0bn, and Pluvicto $1.4bn. Their mix of high sales and still-rising demand keeps them central to Novartis AG’s growth story.
| Drug | 2024 Sales |
|---|---|
| Entresto | $7.8bn |
| Cosentyx | $6.1bn |
| Kisqali | $3.0bn |
| Kesimpta | $3.0bn |
| Pluvicto | $1.4bn |
What is included in the product
Detailed Word Document
Novartis AG BCG Matrix shows which drugs to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page Novartis AG BCG Matrix that quickly shows each unit’s quadrant and reduces strategic confusion
Reference Sources
Novartis AG Reference Sources provide a clear, credible trail that speeds due diligence and supports confident decisions.
Cash Cows
Xolair, mature allergy biologic
Xolair is a classic Cash Cow for Novartis AG: a long-running anti-IgE biologic launched in 2003, with 20+ years of brand depth. It still serves 3 mature areas—severe asthma, chronic spontaneous urticaria, and allergy—and its 2024–2025 demand is steadier than fast-growing, so it throws off cash more than it chases growth.
Jakavi, mature hematology brand
Jakavi remains a cash cow for Novartis AG, with about CHF 1.8 billion in 2025 sales. The JAK inhibitor is a standard option in myelofibrosis and polycythemia vera, so it has a durable niche base. Growth is mature and slower than newer Novartis launches, but the brand still throws off steady cash.
Tafinlar, established melanoma therapy
Tafinlar is a mature BRAF inhibitor in melanoma, so it fits the Cash Cow box: steady demand, low growth, and durable cash flow. In Novartis AG’s latest reported FY2025 oncology mix, this legacy franchise still adds recurring revenue rather than big new growth. The market is stable, not expanding fast, but it keeps paying its way.
Mekinist, established melanoma therapy
Mekinist (trametinib) is a mature MEK inhibitor used in long-running melanoma and other oncology combinations, so demand follows established treatment protocols rather than new adoption. Novartis keeps it in a cash-cow bucket because the asset is steady and clinically entrenched, not a high-growth driver.
Novartis AG reported 2024 net sales of USD 50.3 billion, with oncology among its core franchises, but it does not break out Mekinist sales separately. That lack of fast growth, plus durable use in combo regimens, fits a cash-generating asset more than a growth asset.
- Established melanoma treatment
- Driven by standard care use
- Part of combo oncology franchise
- Stable cash flow, low growth
Zolgensma, high-value rare-disease therapy
Zolgensma remains a cash cow for Novartis AG: the one-time SMA gene therapy carries premium pricing of about $2.1 million in the U.S. and has built an installed base since 2019. Its addressable pool stays small because spinal muscular atrophy incidence is roughly 1 in 10,000 live births, so volume growth is capped by rare-disease incidence. That makes it more cash-rich than growth-rich.
- ~$2.1m U.S. price
- Rare patient pool limits growth
- Installed base supports cash flow
Novartis Cash Cows Keep the Free Cash Flow Coming
Novartis AG’s cash cows are mature brands with stable demand and weak growth, so they keep generating free cash flow. Xolair, Jakavi, Tafinlar, Mekinist, and Zolgensma fit this profile: entrenched use, limited new-patient upside, and dependable revenue in 2025. Jakavi alone delivered about CHF 1.8 billion in 2025 sales.
| Asset | 2025 signal |
|---|---|
| Jakavi | ~CHF 1.8bn sales |
| Xolair | Mature, steady demand |
| Tafinlar | Legacy oncology cash flow |
| Zolgensma | Rare-disease, premium pricing |
Preview the Actual Deliverable
Novartis AG Reference Sources
The Novartis AG BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo version, no hidden changes—just the full, professionally formatted report. It’s ready to download and use right away for analysis, presentations, or strategic planning.
Dogs
Gilenya, post-patent multiple sclerosis brand
Gilenya is a Dogs asset in Novartis AG’s BCG Matrix: after patent expiry, low-cost generics crushed pricing and volume. Sales have fallen from over $3 billion at peak to a residual level by 2025, making it a low-growth, low-share legacy MS brand with limited strategic value.
Lucentis, biosimilar-pressured ophthalmology brand
Lucentis sits in Novartis AG's Dogs: biosimilars Byooviz, approved in 2021, and Cimerli, approved in 2022, cut pricing and share. The anti-VEGF eye market is mature, so Novartis no longer has a clear growth path here. That leaves Lucentis with weaker economics and a declining role in the portfolio.
Exforge, genericized hypertension brand
Exforge, Novartis AG's amlodipine/valsartan brand, is firmly in the Dogs quadrant. It is long past growth, and broad generic competition has stripped most pricing power. As a mature hypertension combo with no high-share growth story left, it is a cash-trap asset rather than a growth driver.
Tasigna, mature CML therapy
Tasigna is a clear Dogs asset in Novartis AG’s BCG view: a mature CML therapy in a crowded market, with growth capped by patent expiry and generic pressure. It remains a legacy revenue line, but its runway is short, so cash generation matters more than expansion. Novartis reported CHF 45.5bn group sales in 2025, while Tasigna now contributes only a small, declining share.
- Legacy CML brand
- Generic pressure after expiry
- Low growth visibility
- Cash over expansion
Afinitor, mature oncology brand
Afinitor is an older mTOR inhibitor in Novartis AG's portfolio, with its oncology peak already behind it. Growth is limited, and the brand is no longer taking meaningful share in mature tumor and transplant use cases.
- Older branded asset
- Peak sales phase passed
- Low growth, flat share
- Dogs profile in BCG Matrix
Novartis Dogs Lag as Legacy Brands Face Erosion
Novartis AG’s Dogs are legacy brands with shrinking sales after patent loss and biosimilar or generic pressure. In 2025, Novartis AG posted CHF 45.5bn sales, while Gilenya, Lucentis, Exforge, Tasigna, and Afinitor now add little growth and face weak pricing power.
| Asset | Dogs signal |
|---|---|
| Gilenya | Generic erosion |
| Lucentis | Biosimilar pressure |
| Tasigna | Patent expiry |
Question Marks
Leqvio, $0.68bn 2024 sales
Leqvio is a twice-yearly inclisiran LDL-lowering therapy, and Novartis reported $0.68bn in 2024 sales. That is still a small base against Novartis’s 2024 group sales of about CHF 50bn, so the product remains a Question Mark in the BCG matrix. Growth is real, but it still needs much wider market penetration to become a clear winner.
Scemblix, $0.71bn 2024 sales
Scemblix posted $0.71bn in 2024 sales, showing strong growth but still a small base versus Novartis AG’s larger oncology brands. The chronic myeloid leukemia asset is still in early scaling, so rising uptake can lift sales further if prescriber adoption keeps broadening. In BCG terms, it fits a Question Mark: high growth potential, but not yet a cash generator.
Fabhalta, 2024 launch
Fabhalta, launched in 2024, is still a Question Mark: Novartis AG has a new oral complement inhibitor in rare hematology and nephrology, but share is still low because the base is young. The franchise addresses PNH and IgA nephropathy, two small but growing markets, so upside can be meaningful if uptake accelerates. Early launch sales are still building, not yet enough to call it a Star.
Remibrutinib, late-stage BTK inhibitor
Remibrutinib is still a clinical-stage BTK inhibitor as of end-2025, so it has no commercial share or product revenue yet. Novartis is running late-stage studies across large inflammatory disease markets, including chronic spontaneous urticaria, a condition affecting about 1 in 10 people at some point in life. That profile fits a Question Mark: high upside, but no proven market position.
- Clinical-stage only; no sales yet
- Targets large, high-growth inflammation markets
- High potential, but share is still zero
Pelacarsen, phase 3 cardiovascular asset
Pelacarsen is a classic question mark for Novartis AG: the phase 3 Lp(a)-lowering program is still waiting on late-stage outcomes, so sales are not yet proven. That matters because cardiovascular prevention is a huge market, with ASCVD causing about 19 million deaths a year worldwide and elevated Lp(a) seen in roughly 1 in 5 people.
- High unmet need, but no commercial share yet
- Late-stage data will decide value
- Big market, still pre-launch risk
Novartis’ Question Marks: Big Potential, Still Small Sales
Leqvio, Scemblix, and Fabhalta each had 2024 sales of $0.68bn, $0.71bn, and launch-stage revenue, while still small versus Novartis AG’s ~CHF 50bn group sales. Remibrutinib and pelacarsen had no sales by end-2025, so their upside is still unproven. These are Question Marks: high growth potential, low share, and execution risk.
| Asset | 2024/2025 status | BCG |
|---|---|---|
| Leqvio | $0.68bn sales | Question Mark |
| Scemblix | $0.71bn sales | Question Mark |
| Fabhalta | Launch sales | Question Mark |
| Remibrutinib | No sales | Question Mark |
| Pelacarsen | Phase 3, no sales | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.